Our Services
Medical Information
Helpful Resources
Published on: 4/9/2026
If your weight is not budging on a GLP-1, that is common and often reflects dose titration, normal plateaus and metabolic adaptation, lifestyle factors like low protein or activity, or conditions such as hypothyroidism, PCOS, sleep apnea, or medication effects; remember that 5 to 10 percent loss already brings meaningful health gains.
Next steps include confirming you are at the right dose and using it correctly, optimizing protein and resistance training, improving sleep and stress, screening for medical contributors, and discussing medication adjustments or combination therapy, with urgent care for severe symptoms; see below for the complete, step by step guidance and red flags that could change your plan.
If you're taking a GLP-1 medication and the scale isn't moving the way you expected, you're not alone. These medications have changed the landscape of obesity treatment—but they are not magic. And when weight loss slows down or stalls, it can feel frustrating and confusing.
Let's walk through what's normal, what's not, and what you can realistically do next—based on credible medical evidence and current clinical guidance.
GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces in the gut. It helps regulate:
GLP-1 receptor agonist medications (often simply called "GLP-1 medications") mimic this hormone. They:
Some well-known GLP-1 medications are approved for type 2 diabetes, obesity, or both. In clinical trials, people taking GLP-1 medications for obesity lost 5% to 20% of their body weight, depending on the medication and dose.
That's significant. But results vary.
If your weight won't budge, it does not automatically mean the medication "isn't working." Several factors can influence your results.
Most GLP-1 medications are started at a low dose and slowly increased over weeks or months. This helps reduce side effects like nausea.
Weight loss often becomes more noticeable after:
If you're still in the dose-escalation phase, it may simply take time.
Weight loss is not linear. Even with GLP-1 treatment:
This is not failure. It's biology.
The body is wired to resist weight loss. Hormones shift, energy expenditure drops, and hunger signals can subtly increase—even while on medication.
GLP-1 medications reduce appetite—but they don't completely override behavior or environment.
If weight loss has stalled, consider:
Research shows that combining GLP-1 therapy with:
improves fat loss and helps maintain muscle mass.
Sometimes weight doesn't respond as expected because of other health conditions, including:
If you haven't had a full medical review, this is an important next step.
To help identify potential factors that might be affecting your weight loss progress, you can use Ubie's free AI-powered Obesity symptom checker to gather insights before discussing them with your healthcare provider.
GLP-1 medications are powerful—but they are not cosmetic weight-loss drugs.
Medical guidelines define successful obesity treatment as:
Why? Because even that amount can significantly reduce:
If you've already lost 7–10%, you may be experiencing meaningful health benefits—even if it's less than you hoped.
A plateau generally means:
If that's happening, here are medically supported next steps.
Ask your doctor:
Small adjustments sometimes make a significant difference.
On GLP-1 medications, appetite is lower—which can lead to:
Loss of muscle can slow metabolism.
Focus on:
Poor sleep and chronic stress increase cortisol, which can:
Sleep apnea is especially common in people with obesity and can significantly blunt weight loss progress.
If you snore heavily or feel unrefreshed after sleep, speak to your doctor.
Emerging research supports combining GLP-1 medications with:
This is not appropriate for everyone, but it may be worth discussing if progress has stalled.
Weight is one metric. But it's not the only one.
Ask:
Health improvement can occur even when the scale slows down.
Most weight plateaus are normal. However, speak to a doctor promptly if you experience:
While serious side effects are uncommon, they require immediate medical evaluation.
If something feels urgent or potentially life-threatening, seek medical care immediately.
Obesity is recognized by major medical organizations as a chronic, relapsing disease—not a failure of willpower.
GLP-1 medications help regulate the biological drivers of hunger and metabolism. But like treatments for high blood pressure or diabetes, they often require:
Stopping GLP-1 therapy frequently leads to weight regain. This isn't personal failure—it reflects underlying biology returning.
That's why obesity management should be treated as chronic care, not a short-term fix.
It's normal to feel frustrated if:
But remember:
If you're uncertain about what's happening with your weight or want to explore other symptoms that could be impacting your progress, check your Obesity-related symptoms with Ubie's AI-powered tool to prepare for a more productive conversation with your doctor.
If your weight won't budge on a GLP-1 medication:
GLP-1 therapy is evidence-based and effective—but it works best as part of a comprehensive medical plan.
Most importantly, don't navigate this alone. Speak to a qualified healthcare professional about any concerns, especially if symptoms feel severe, unusual, or potentially serious. Obesity is a medical condition, and you deserve thoughtful, personalized care.
Progress may not always be fast—but it can still be meaningful.
(References)
* Wilding JPH, Batterham RL, Bajaj HS, Kadowaki T, Van Der Ploeg L, Kushner RF, Wadden TA, Buse JB. Weight Loss and Maintenance with Semaglutide 2.4 mg in Adults with Overweight or Obesity: A Systematic Review. Adv Ther. 2023 Jul;40(7):3158-3174. doi: 10.1007/s12325-023-02555-z. Epub 2023 Jun 2. PMID: 37267154; PMCID: PMC10287265.
* Singh G, D'Souza S, Singh S, Al-Dahhan Z, Patel A. Efficacy and Safety of Tirzepatide in Weight Loss in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis. Cureus. 2024 Jan 15;16(1):e52336. doi: 10.7759/cureus.52336. PMID: 38361657; PMCID: PMC10866870.
* Astley CM, Rader DV, Ritchie SC. Genetic Predictors of Weight Loss Response to GLP-1 Receptor Agonists. Diabetes. 2024 Mar 1;73(3):363-366. doi: 10.2337/dbi23-0005. PMID: 38411648.
* Finer N, Caterson ID, Nadolsky K, Kushner RF. Optimizing outcomes in obesity management with GLP-1 receptor agonists. Diabetes Obes Metab. 2022 Mar;24(3):398-411. doi: 10.1111/dom.14611. Epub 2022 Jan 19. PMID: 34994017; PMCID: PMC9292837.
* Kones RB. Obesity treatment: current and future medical approaches, diet and lifestyle, and surgery. Int J Clin Pract. 2023 Sep;77(9):e16194. doi: 10.1111/ijcp.16194. Epub 2023 May 19. PMID: 37207452.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.